| Basics |
| Company: |
Altimmune, Inc. |
| IPO Date: |
May 22, 2017 |
| Sector: |
Healthcare |
| Industry: |
Biotech |
| Market Cap: |
$457.33M |
| Activated in VL: |
True |
| Average Daily Range |
| Avg Daily Range: |
$0.32 | 4.19%
|
| Avg Daily Range (30 D): |
$0.16 | 2.32%
|
| Avg Daily Range (90 D): |
$0.25 | 3.30%
|
| Institutional Daily Volume |
| Avg Daily Volume: |
1.64M |
| Avg Daily Volume (30 D): |
1.96M |
| Avg Daily Volume (90 D): |
2.65M |
| Trade Size |
| Avg Trade Size (Sh.): |
155 |
| Avg Trade Size (Sh.) (30 D): |
135 |
| Avg Trade Size (Sh.) (90 D): |
140 |
| Institutional Trades |
| Total Inst.Trades: |
1,313 |
| Avg Inst. Trade: |
$1.78M |
| Avg Inst. Trade (30 D): |
$.84M |
| Avg Inst. Trade (90 D): |
$1.03M |
| Avg Inst. Trade Volume: |
.18M |
| Avg Inst. Trades (Per Day): |
1 |
| Market Closing Trades |
| Avg Closing Trade: |
$2.08M |
| Avg Closing Trade (30 D): |
$.85M |
| Avg Closing Trade (90 D): |
$1.07M |
| Avg Closing Volume: |
223.21K |
|
|
|
|
| News |
Feb 21, 2025 @ 6:00 PM
Evolving Landscape of Obesity: Key Market Insights...
Source: Delveinsight
|
Jan 30, 2025 @ 4:03 PM
Sprout Social, Altimmune, Equinix, and Globe Life ...
Source: Johnson Fistel, Llp
|
Dec 19, 2024 @ 11:35 PM
Why Altimmune Was Such a Robustly Healthy Stock on...
Source: Eric Volkman
|
Nov 15, 2024 @ 4:00 PM
Altimmune Presents New Data on the Effect of Pemvi...
Source: Altimmune, Inc.
|
Sep 17, 2024 @ 2:15 PM
Prediction: This Will Be the First Healthcare Stoc...
Source: The Motley Fool
|
| Financials |
| |
TTM |
Q2 2024 |
Q1 2024 |
|
Basic EPS
|
$-.32
|
$-.35
|
$-.34
|
|
Diluted EPS
|
$-.32
|
$-.35
|
$-.34
|
|
Revenue
|
$ .01M
|
$ .01M
|
$ .01M
|
|
Gross Profit
|
$
|
$
|
$
|
|
Net Income / Loss
|
$ -22.85M
|
$ -24.64M
|
$ -24.39M
|
|
Operating Income / Loss
|
$ -24.77M
|
$ -26.75M
|
$ -26.79M
|
|
Cost of Revenue
|
$
|
$
|
$
|
|
Net Cash Flow
|
$ -25.65M
|
$ -21.85M
|
$ -56.14M
|
|
PE Ratio
|
|
|
|
| Splits |
| Sep 14, 2018:
30:1
|
| May 05, 2017:
10:1
|
| May 04, 2017:
10:1
|
| Jul 25, 2007:
50:1
|
|
